MERCURY PE

Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism from the Emergency Department (MERCURY PE)

Objective

This study is being conducted in partnership with the Midwest Cardiovascular Research Foundation.

The purpose of this study is to compare the effects (both good and bad) of rivaroxaban to those of the local standard of care at the hospital for patients who have been diagnosed with a blood clot to/from their lung, called a pulmonary embolism (PE).

Standard of care is the hospital’s treatment guideline, which is being admitted to the hospital and being treated with another drug(s) that treats blood clot in the lung. It is possible that the standard of care drug that is used at the hospital may be rivaroxaban. This study is designed to determine whether it is safe to treat patients with a low risk pulmonary embolism as an out-patient, meaning no hospital admission. 

Principal Investigator(s)
Nicholas Shammas

Clinical Trial Categories

  • Cardiac Research
Sponsor(s)
Janssen Scientific Affairs, LLC
Contact
Midwest Cardiovascular Research Foundation at 563-324-2828

Location

  • Medical Center, East Rusholme Street
    1227 East Rusholme Street
    Davenport, IA 52803
    Main: 563-421-1000

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email